PK MED
PK MED is a French clinical-stage biotech developing injectable, biodegradable micro-implants that deliver drugs locally for gout flares (PKM-01), osteoarthritis (PKM-011), and hematopoietic stem cell transplantation (PKM-02), targeting patients with rheumatologic and hematologic conditions.
- Company typePrivate
- Founded2019
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PK MED does
PK MED is a French clinical-stage biotechnology company founded in 2019 with backing from Truffle Capital, headquartered in Paris with R&D operations in Lyon. The company develops custom-designed, injectable, biodegradable micro-implants that release therapeutic molecules in a controlled and localized manner, addressing unmet needs in rheumatology and hematopoietic stem cell transplantation. Its pipeline comprises three programs: PKM-01, an intra-articular colchicine drug product for gout flares (FDA-cleared for Phase 2 in February 2024); PKM-011, a long-acting colchicine derivative for osteoarthritis; and PKM-02, a cell-homing implant designed to enhance engraftment in hematopoietic stem cell transplantation for hemoglobinopathies and related indications.
The underlying platform is a proprietary, patented local therapy technology that combines known active ingredients with a biodegradable delivery matrix, enabling high local drug concentration, rapid onset (e.g., 5-minute pain relief for PKM-01), extended duration (7-day coverage of gout flares), and reduced systemic exposure. PKM-01 pursues the FDA 505(b)(2) pathway, an abbreviated regulatory route for reformulations of known compounds, which compresses development timelines relative to novel chemical entities. The company maintains a Scientific Advisory Board of KOLs in rheumatology and hematology, including advisors from leading US and European institutions, and is governed by a board chaired by Yvonne Bokelman (appointed July 2024).
PK MED is pre-revenue and has not yet commercialized any product. Its business model centers on clinical development of proprietary pharmaceutical products for sale through prescription channels (physicians, hospitals, specialty pharmacies) upon regulatory approval, with the company explicitly seeking co-development and commercialization partnerships. Capital structure to date relies on founding investment from Truffle Capital and non-dilutive public financing, including a €1.5 million Bpifrance DeepTech grant awarded in July 2024 for PKM-02 development, and regional support from Auvergne-Rhône-Alpes. Customer segments are defined by therapeutic use case rather than by enterprise procurement, targeting gout patients (primary), osteoarthritis patients, and patients eligible for hematopoietic stem cell transplantation.
PK MED firmographics
Firmographics- Name
- PK MED
- Legal name
- PK MED
- Website
- https://pk-med.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PK MED is a French clinical-stage biotech developing injectable, biodegradable micro-implants that deliver drugs locally for gout flares (PKM-01), osteoarthritis (PKM-011), and hematopoietic stem cell transplantation (PKM-02), targeting patients with rheumatologic and hematologic conditions.
- Ownership category
- akta.pro rank
PK MED industry classification
Industry- Product category
- Biopharmaceuticals (Drug Delivery Implants)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
- akta.pro secondary industry
- Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI)
Keywords
Where PK MED is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
PK MED business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical product sales: PK MED is developing pharmaceutical products (PKM-01 for gout flares, PKM-02 for bone marrow transplantation) and will commercialize them through prescription channels upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
PK MED product offering
Product offeringCore offering
PK MED designs and develops custom, injectable, biodegradable micro-implants that deliver known drugs (such as colchicine) in a controlled and localized manner for the treatment of rheumatologic and hematologic diseases. Its lead program PKM-01 is an intra-articular colchicine implant for gout flares, supported by a pipeline that includes PKM-011 for osteoarthritis and PKM-02 for cell-homing in hematopoietic stem cell transplantation. The company is clinical-stage and will commercialize approved products through prescription pharmaceutical channels and strategic partnerships.
Product overview
PK MED is a French biotech company that develops custom-designed, injectable, biodegradable micro-implants for local drug delivery and cell-homing therapies. The company's product portfolio includes three main programs: PKM-01 (intra-articular colchicine for gout flares), PKM-011 (long-acting colchicine derivative for osteoarthritis), and PKM-02 (cell-homing implant for bone marrow transplantation in hemoglobinopathies). PKM-01 is the most advanced program, having received FDA clearance to initiate a Phase 2 clinical trial. The company leverages proprietary drug delivery technology to enable controlled, localized release of therapeutics, improving efficacy and safety compared to systemic treatments.
Differentiator
Problem solved
Functional benefit
Brands
- PKM-01: Intra-articular colchicine drug product for treatment of gout flares. The first ever intra-articular colchicine drug product, providing fast-acting pain relief within 5 minutes, strong efficacy through high local drug concentration, and favorable safety profile by limiting systemic exposure.
- PKM-011
- PKM-02
Products and services
- PKM-01 The first-ever intra-articular colchicine drug product, combining a controlled-release form of colchicine with a fast-acting anesthetic for the local treatment of gout flares. A single intra-articular administration provides pain relief within 5 minutes and 7 days of coverage over the entire flare, with strong local efficacy and a favorable systemic safety profile suitable for patients with contraindications to NSAIDs, oral colchicine, or glucocorticoids.
- PKM-011 A long-acting intra-articular colchicine derivative built on PKM-01's platform, in development for the treatment of osteoarthritis. Targets a degenerative joint disease affecting 500 million people worldwide, where few pharmacological options exist and current treatments have major limitations in efficacy and safety.
- PKM-02 A cell-homing technology implant designed to enhance hematopoietic stem cell transplantation (HSCT) outcomes. Administered as a local injection prior to HSCT to foster cell homing and engraftment, with the first indication targeting hemoglobinopathies. Aims to increase the probability of finding matched donors and enable curative treatment in adult hemoglobinopathy patients, with potential applicability to other tissue regeneration indications.
Quantifiable outcome
- Fast pain relief within 5 minutes
- +3 more outcomes
Companies that use PK MED
Customer profileSegments3 records
Ideal customer profiles4 records
PK MED technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PK MED partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
PK MED competitors and assessment
Company assessmentEmerging players
- Tarsus Pharmaceuticals: Tarsus applies novel formulation/delivery of established molecules to address underserved specialty indications. While focused on ophthalmic/eye care, its strategy of repurposing known compounds via innovative delivery parallels PK MED's approach with colchicine.
- Cartesian Therapeutics: Cartesian develops RNA cell therapies with novel delivery technologies and includes the legacy Selecta Biosciences pipeline. Its platform-style approach to engineered/localized therapeutics is thematically comparable to PK MED's drug delivery platform.
- Actinium Pharmaceuticals: Actinium develops targeted conditioning regimens for HSCT and cell therapies. Its work on improving transplant outcomes via novel delivery/targeting approaches is comparable to PK MED's PKM-02 local cell-homing implant.
- Selecta Biosciences: Selecta developed ImmTOR immune tolerance platform using novel nanoparticle delivery. While focused on biologics/immunology, its platform-based local drug delivery work is thematically aligned with PK MED's controlled-release micro-implant concept.
Others
- Truffle Capital: Truffle Capital is the founding investor of PK MED and a European life sciences VC; included here as an ecosystem participant and potential comparator for similarly staged portfolio companies in EU biotech, rather than a direct product competitor.
Direct peers
- Heron Therapeutics: Heron develops locally delivered, long-acting therapeutics using proprietary polymer-based delivery (e.g., HTX-011 for postsurgical pain). Its technology platform and local-delivery focus are directly comparable to PK MED's micro-implant approach.
- Eupraxia Pharmaceuticals: Eupraxia develops injectable, sustained-release therapeutics using a proprietary polymer microsphere platform (e.g., EP-104 for OA). Its technology and indication overlap directly with PK MED's PKM-011 intra-articular OA program and micro-implant delivery approach.
- Magenta Therapeutics: Magenta developed conditioning and stem cell mobilization therapies for hematopoietic stem cell transplantation, directly comparable to PK MED's PKM-02 cell-homing HSCT program targeting hemoglobinopathies and related blood disorders.
Broad incumbents
- Bioventus: Bioventus is a broader orthopedic care company offering intra-articular osteoarthritis treatments (e.g., DUROLANE). While diversified, its OA-focused product line addresses the same patient population targeted by PK MED's PKM-011.
- Pacira BioSciences: Pacira is a specialty pharma leader in local drug delivery (e.g., EXPAREL for postsurgical pain) and acquired Flexion Therapeutics for intra-articular OA treatments. It is a broad incumbent whose local-delivery portfolio overlaps with PK MED's micro-implant approach to local therapeutics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
PK MED social profiles
Digital presencePK MED financial estimates
Financial estimateRevenue estimate
Valuation estimate
PK MED leadership team
Management profileNumber of profiles
Profiles18 records
PK MED funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PK MED M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PK MED
What does PK MED do?
PK MED designs and develops custom, injectable, biodegradable micro-implants that deliver known drugs (such as colchicine) in a controlled and localized manner for the treatment of rheumatologic and hematologic diseases. Its lead program PKM-01 is an intra-articular colchicine implant for gout flares, supported by a pipeline that includes PKM-011 for osteoarthritis and PKM-02 for cell-homing in hematopoietic stem cell transplantation. The company is clinical-stage and will commercialize approved products through prescription pharmaceutical channels and strategic partnerships.
Is PK MED a public or private company?
PK MED is a private company. It is classified as venture growth investor backed and is currently operating.
When was PK MED founded?
PK MED was founded in 2019. It employs 1 to 10 people.
Where is PK MED based?
PK MED is headquartered in Paris, France, in the Europe region.
How does PK MED make money?
One revenue line is on record: pharmaceutical product sales.
Who are PK MED's main competitors?
Emerging players on record are Tarsus Pharmaceuticals, Cartesian Therapeutics, Actinium Pharmaceuticals and Selecta Biosciences. Truffle Capital is listed as an others. Direct peers are Heron Therapeutics, Eupraxia Pharmaceuticals and Magenta Therapeutics. Broad incumbents are Bioventus and Pacira BioSciences.
Does PK MED have an API?
No public API is recorded for PK MED.
What industry is PK MED in?
PK MED's product category is Biopharmaceuticals (Drug Delivery Implants). Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring, with a secondary code of HLAKAFAI, Bone Marrow & Stem Cell Transplant (BMT/HSCT). Its NAICS code is 3254 and its SIC code is 2834.